Phase II study of Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1/oxaliplatin(SOX)+bevacizumab regimen for advanced colorectal cancer

ABSTRACT: Interventions: Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1/oxaliplatin(SOX)+bevacizumab regimen Primary outcome(s): Adverse events Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2630776 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR